University of Wisconsin, Madison
1,363
160
221
901
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
12.2%
166 terminated/withdrawn out of 1363 trials
84.4%
-2.1% vs industry average
10%
130 trials in Phase 3/4
40%
363 of 901 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (1363)
Defy The Odds: Exercise Forecasting and Motivation Strategies for Prolonged-Sitting Jobs
Role: lead
A Pilot Study of Local Anesthesia for Inguinal Hernia Surgery in Older Adults
Role: lead
Leveraging Artificial Intelligence to Prevent Vision Loss From Diabetes
Role: lead
Mental Health App for Cancer Survivors Study
Role: lead
Seroprevalence of Hepatitis E in People With an Organ Transplant
Role: collaborator
Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults
Role: lead
Cognitive Behavioral and Faith Fellowship to Improve Thy Health
Role: lead
Evaluating the Impacts of Informal Tick and Tickborne Disease Educational Tools on Children
Role: lead
Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls
Role: lead
LapBox® Manual Containment System
Role: lead
Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy
Role: lead
Interventions to Enhance Quadriceps Output After ACLR
Role: lead
Temporal Interference for Thalamocortical Activity and Network Modulation
Role: lead
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
Role: lead
PET/CT Characterization of Treatment Resistance
Role: lead
Testing a Digital Mindfulness Program to Support People Experiencing Suicidal Thoughts
Role: lead
Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis
Role: lead
Worldwide Yearly Screening for Hypospadias
Role: lead
A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer
Role: lead
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
Role: lead